TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Carbohydrate Antigen 125-guided Therapy in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older.~* At least 1 admission for AHF, in the last 180 days.~* Demonstrates functional New York Heart Association status of Class ≥II at the moment of enrollment.~* Objective evidence, either during the index admission or at least 180 days before enrollment, of a structural or functional abnormality of the heart at rest, and defined as: N terminal-pro-brain natriuretic peptide \>1000 pg/ml or brain natriuretic peptide \>100 pg/ml or echocardiographic abnormalities congruent with HF diagnosis such as: systolic left ventricular dysfunction (LVEF \<50%); left ventricular hypertrophy (defined as left ventricular septum or left ventricular posterior wall thickness ≥12 millimeters or left ventricular mass index \>104 g/m2 in women or 116 g/m2 in men); Ee'\>15 or significant valvular heart disease (moderate-severe).~* A plasma CA125 value \>35 U/ml in a recent test evaluation (at least 30 days before enrollment, and preferably assessed before hospital discharge).~* Patient must be capable of understanding and signing an informed consent form.~Exclusion Criteria:~* Life expectancy \<12 months due to other diseases different from HF.~* Having undergone a cardiac transplantation, coronary revascularization procedure (percutaneous coronary intervention and/or coronary artery bypass grafting) or cardiac valve replacement in the past 3 months.~* Angina pectoris higher than class II (Canadian Cardiovascular Society Classification).~* Pregnancy at the moment of enrollment.~* Valvular heart disease already scheduled for surgical intervention.~* Severe chronic obstructive and/or restrictive pulmonary disease, requiring continuous oxygen administration.~* Serum creatinine level \> 3 mg/dl or chronic renal insufficiency on dialysis treatment.~* Patients receiving resynchronization therapy during the index admission.~* Significant concurrent medical diseases including cancer or a history of cancer within 5 years of entering the screening period, endometriosis, cirrhosis, acute coronary syndrome within 6 months, uncontrolled hypertension, history of human immunodeficiency virus (HIV) infection, or a significant active infection.~* Participating in another randomized study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CA125 guided strategy (Type: EXPERIMENTAL): In this group, physician will be encouraged to maximize all treatment measures aimed to keep CA125≤35 U/ml (normal values).
- Standard treatment strategy (Type: ACTIVE_COMPARATOR): Therapy is based on established european current guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* voiding frequency 8 or above per day~* at least one incontinence episode per day~* age between 5-10 years~* body weight between 17 and 45 kg~Exclusion Criteria:~* normal age expected bladder capacity~* PVR more than 10 ml~* dysfunctional voiding~* neurogenic disorders~* UTI, constipation

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male patients ranging from 25 to 65 years.~2. Type 1 or type 2 diabetic patients with a personal history of diabetes ≥ 5 years.~3. History of chronic erectile dysfunction for at least six months.~4. HbA1c ≤ 10%.~5. Baseline International Index of Erectile Function (IIEF) score of \< 26.~6. Not interested or able to use Phosphodiesterase type 5 inhibitor (PDE-5i) drug therapy and willing to forgo these treatments for the first 6 month period following study treatment.~7. Body mass index between 20 -30.~8. Willing to provide written informed consent, complete questionnaire, and to be available for all baseline treatment and follow up examinations required by protocol.~Exclusion Criteria:~1. Untreated hypogonadism or low serum total testosterone \< 200 ng/dl.~2. Current urinary tract or bladder infection.~3. Any medical evidence of any infectious disease.~4. Clinically evident penile anatomical deformities (e.g., Peyronie's disease) or history of priapism.~5. Skin irritation, infection, wound, sore or disruption in the immediate areas of skin entry for penile injection.~6. Current or previous malignancy.~7. Patients with primary hyperlipidemia.~8. Use of any non study treatment for erectile dysfunction within 4 weeks of study treatment.~9. Lack of willingness to continue through 6 months after study treatment.~10. Any previous penile implant or penile vascular surgery.~11. Uncontrolled hypertension or hypotension (systolic blood pressure \> 170 or \< 90 mm Hg, and diastolic blood pressure \> 100 or \< 50 mm Hg).~12. Reported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart failure) or symptomatic postural hypotension within 6 months before screening.~13. Bleeding or clotting disorder, use of anticoagulant therapy.~14. Lab values for complete blood count, prothrombin time/ partial thromboplastin time/international randomized ratio (PT/PTT/INR), Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine falling outside the normal lab values.~15. Systemic autoimmune disorder.~16. Significant active systemic or localized infection.~17. Receiving immunosuppressant medications.~18. HbA1c \> 10%.

- Gender: MALE
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- autologous mesenchymal stem cells (Type: EXPERIMENTAL): Intervention:~Autologous bone marrow derived stem cells will be injected twice intracavernously to enrolled erectile dysfunction patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BAX 326 Surgery Study in Hemophilia B Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Participant and/or legal representative has/have voluntarily provided signed informed consent.~* Participant has severe (FIX level \< 1%) or moderately severe (FIX level 1-2%) hemophilia B (based on the one stage activated partial thromboplastin time (aPTT) assay), as tested at screening at the central laboratory.~* Participant requires surgery~* Participant has previously been treated with plasma-derived and/or recombinant FIX concentrate(s) for a minimum of 150 exposure days~* Participant has no evidence of a history of FIX inhibitors~* Participant is immunocompetent as evidenced by a CD4 count ≥ 200 cells/mm3.~* Participant is human immunodeficiency (HIV) negative or is HIV+ with a viral load \< 200 particles/μL \~ \< 400,000 copies/mL.~Main Exclusion Criteria:~* Participant has a history of FIX inhibitors with a titer ≥ 0.6 Bethesda Units (BU) (as determined by the Nijmegen modification of the Bethesda assay or the assay employed in the respective local laboratory) at any time prior to screening.~* Participant has a detectable FIX inhibitor at screening, with a titer ≥0.6 Bethesda Units (BU) as determined by the Nijmegen modification of the Bethesda assay in the central laboratory.~* Participant has a history of allergic reaction or evidence of an ongoing or recent thrombotic disease, fibrinolysis or disseminated intravascular coagulation (DIC).~* Known hypersensitivity to hamster proteins or recombinant furin.~* Evidence of an ongoing or recent thrombotic disease, fibrinolysis or disseminated intravascular coagulation (DIC).~* Abnormal renal function~* Severe chronic liver disease~* Active hepatic disease with ALT or AST levels \> 5 times the upper limit of normal.~* Diagnosis of an iherited or acquired hemostatic defect other than hemophilia B.~* Platelet count \< 100,000/mL.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BAX326 in Surgery (Type: EXPERIMENTAL): BAX 326 (recombinant factor IX) in Surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Meropenem Dosage Strategy Based on PPK Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sixty years and older patients hospitalized at the Peking University Third Hospital with community-acquired or hospital-acquired lower respiratory tract infection.~* Bacilli was idolated from lower respiratory tract specimens within 48 hours prior to study enrollment.~* The pathogen was sensitive to meropenem.~* Received broad-spectrum antibiotic therapy less than 24 hours, or no improvement after antibiotic therapy and pathogen was resistant to the used antibiotics.~Exclusion Criteria:~* Had documented hypersensitivity to carbapenems.~* More than one pathogenic Gram-negative bacillus was isolated lower respiratory tract specimens.~* Positive HIV antibody titre.~* Had known or suspected tuberculosis or other infections caused by Gram-positive cocci, viruses or fungi at baseline.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: ACTIVE_COMPARATOR): The participants in control group will accept routine meropenem therapy
- Study group (Type: EXPERIMENTAL): The participants in study group will accept meropenem therapy based on a PPK and PD model.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion/ Exclusion Criteria~Key Inclusion Criteria:~* Adult participant (18 years and over)~  * treated for one of the following conditions: RA, AS, PsA, CD, UC.~ * either active substance naïve or treated with the originator or another biosimilar at baseline.~ * for whom the treating physician has decided to treat by (naïve) or switch from originator or another biosimilar to Flixabi or Imraldi.~ * participants who had initiated Flixabi or Imraldi at most 12 months before the baseline will also be included in the cohort.~* Paediatric participants (6-17 years):~  * treated for one of the following conditions: CD, UC.~ * either active substance naïve or treated with another biosimilar at baseline.~ * for whom the treating physician has decided to treat by (naïve) or switch to Flixabi (for both indications) or Imraldi (only for Crohn's disease).~ * participants who had initiated Flixabi or Imraldi at most 12 months before the baseline will also be included in the cohort.~Key Exclusion Criteria:~* Participant treated for psoriasis.~* Participant who are not to be followed up in the same investigator site for 2 years after baseline.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Flixabi (Type: None): Infliximab naive participants or participants who were previously treated with other infliximab biologics will receive Flixabi (infliximab) as prescribed by physician according to the local prescribing procedures.
- Imraldi (Type: None): Adalimumab naive participants or participants who were previously treated with other adalimumab biosimilars will receive Imraldi (adalimumab) as prescribed by physician according to the local prescribing procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Effect of VIA-2291 on Vascular Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients are to be of non-childbearing potential~* Patient has suffered an ST elevation myocardial infarction (MI), non-ST elevation MI, or unstable angina 21 days (±3 days) prior to study randomization~* Patient has documented coronary artery disease~Exclusion Criteria:~* Renal insufficiency defined as creatinine \>1.5 x upper limit of normal (ULN)~* Cirrhosis, recent hepatitis, ALT \>1.5 x ULN or ALT \> 1 x ULN and at least one other liver function test~* Uncontrolled diabetes mellitus within 1 month prior to study screening~* Congestive heart failure (CHF) defined by the New York Heart Association as functional Class III or IV~* Previous coronary artery bypass graft (CABG) surgery~* Planned additional cardiac intervention~* Recurrence of ST elevation MI, non-ST elevation MI, or unstable angina less than 18 days prior to randomization~* Current atrial fibrillation, atrial flutter, or frequent premature ventricular contractions~* Acetaminophen use in any form in the 7 days before enrollment

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- VIA-2291 25 mg (Type: EXPERIMENTAL): VIA-2291 25 mg
- VIA-2291 50 mg (Type: EXPERIMENTAL): VIA-2291 50 mg
- VIA-2291 100 mg (Type: EXPERIMENTAL): VIA-2291 100 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects of Chinese descent with full Chinese parentage.~2. Diagnosis of Crohn's disease (CD) for at least 3 months prior to Week 0 confirmed by endoscopy, radiologic evaluation, and/or histology during the Screening Period.~3. Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450 despite treatment with oral corticosteroids and/or immunosuppressants.~4. Subject has a negative Tuberculosis (TB) Screening Assessment.~Exclusion Criteria:~1. Subject with ulcerative colitis or indeterminate colitis.~2. Subject who has had a surgical bowel resection within the past 6 months or who is planning any resection at any time point in the future.~3. Subject with an ostomy or ileoanal pouch.~4. Subject who has short bowel syndrome.~5. Subject with symptomatic known obstructive strictures.~6. Subject with an internal or external fistula (with the exception of an anal fistula without abscess).~7. Chronic recurring infections or active TB.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Low Induction Dose (Type: EXPERIMENTAL): Participants received the low loading dose of adalimumab (80 mg at Week 0) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 2, 4, and 6.
- Standard Induction Dose (Type: EXPERIMENTAL): Participants received the standard loading dose of adalimumab (160 mg at Week 0 and 80 mg at Week 2) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 4 and 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participated in a previous brentuximab vedotin study.~* CD30-positive hematologic malignancy.~* At a minimum, experienced clinical benefit in the prior brentuximab vedotin study. For retreatment, patients must have previously achieved either complete or partial remission with brentuximab vedotin and experienced disease progression after discontinuing the prior brentuximab vedotin study.~Exclusion Criteria:~Withdrew consent to participate in any prior brentuximab vedotin study.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BV Retreatment (Type: EXPERIMENTAL): Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (retreatment after relapse)
- BV Extension (Type: EXPERIMENTAL): Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (continued treatment)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Instillation and Packing in Mydriasis for Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* gestational age of less than 32 weeks and/or the birth weight of less than 1,500 grams~* stable clinical course~Exclusion Criteria:~* history of intraocular surgery or laser treatment~* previous eyedrop instillation that might affect the pupil size~* severe underlying disease or unstable clinical course that mydriatic drugs or the examination could aggravate their conditions

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 4 Months
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Lower conjunctival fornix packing arm. For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix.
- 2 (Type: ACTIVE_COMPARATOR): Conventional instillation arm. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Serum Uric Acid ≥6.0 mg/dL~* eGFR ≥30 mL/min/1.73 m2~* UACR between 30 mg/g and 3500 mg/g inclusive~* Diagnosed with T2DM~Exclusion Criteria:~* Treated with any drug for hyperuricemia in the 6 months preceding randomization.Drugs for hyperuricemia include all XO inhibitors (allopurinol, febuxostat and topiroxostat) and URAT1 inhibitors (lesinurad, verinurad, probenecid, and benzbromarone)~* Prior history of gout, unless prophylaxis therapy isn't required~* Patients who are pregnant, lactating, or planning to become pregnant~* Patients unsuitable or unable to undergo MRI assessment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Verinurad 9 mg+Febuxostat 80 mg (Type: EXPERIMENTAL): Capsule administered orally, once daily for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Capsule administered orally, once daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Men and women aged 20 years or older at the time of enrollment~2. Patients with RRMM~3. Participants who are scheduled to start IRd therapy~4. Participants who can provide written informed consent of their own free will before the start of study treatment~5. Participants who are judged by the principal investigator or investigator(s) to have the faculty to understand and comply with the requirements of the study~Exclusion Criteria:~1. Female Participants who are nursing or pregnant~2. Participants who have been treated with ixazomib~3. Participants with hypersensitivity to any of the components of IRd therapy, their analogs or excipients~4. Participants with another active malignancy, i.e. synchronous active malignancy or previous malignancy with a disease-free period of less than 5 years, except for participants with carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma judged to be cured by topical treatment~5. Participants who are not registered with, or comply with, the guidelines of the lenalidomide management program~6. Participants who, in the judgement of the principal investigator or investigator(s), are considered to be unsuitable for enrolment into the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixazomib + Lenalidomide + Dexamethasone (Type: None): Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete